Marco Dotto
Treviso, Veneto, Italia
7545 follower
Oltre 500 collegamenti
Informazioni
I’m a 4x founder and CEO, 4x business angel and 3x VC investor with 15 years of experience in genomics, life sciences, longevity biotech and healthcare.
I co-founded and managed as CEO the 1st genomics companies applying Next Generation Sequencing to provide:
- Whole Genome Sequencing and genomic interpretation for rare disease diagnostics
- DTC personalized genomics analysis based on WGS and WES
- Non Invasive Prenatal Tests based on circulating cell-free fetal DNA sequencing
- Multi-omics and liquid biopsy analyses for personalized cancer therapy
to the Italian market.
I have managed the start-up, scale-up & exit of several companies that have leveraged disruptive technologies to improve patients' health:
- Personal Genomics (acquired by the multinational company SOL S.p.A.)
- Biodiversa
- Sorgente Oncologia
- DNA Consulting
I have also managed the global scouting of startups and the strategic partnerships for Angelini Ventures, the Corporate Venture Capital fund of Angelini Industries, with 300 M € of AUM investing in disruptive digital health & life sciences startups.
My personal and professional mission is to transform patients lives by making disruptive and transformative technologies accessible at a global scale.
I worked on this mission as a startup and scale-up entrepreneur / CEO 1st, as a consultant for small and large US and EU companies and then as a VC and business angel getting experience on both the investor and entrepreneur sides.
My genomics companies managed hundreds of clinical research and diagnostics projects in oncology, immunology, genetics, rare diseases and virology that led to hundreds of publications in top impact factor scientific journals.
I have managed strategic partnerships globally connecting investors, talents, researchers, techologies and business experts.
I’m focused on the tech scouting and scale up of the latest innovations to be the catalyst for impactful and exponential improvements that could reshape healthcare globally.
I'm also a Limited Partner of 3 seed & series A Venture Capital funds (Unruly Capital, Eden Ventures, Moonstone).
Unruly Capital is focused on disruptive deep techs:
- Climate Tech: Energy, Electrification, FoodTech, Agriculture, Construction
- Future Tech: Space, Synthetic Biology, New materials, AI
- MedTech & Longevity: Drug discovery, MedTech, New compounds, Psychedelics, Genetic engineering, Biotech
- Decentralization: Food & Energy production, 3D Printing, Recycling, Resilient supply chains
I also founded a syndicate of investors focused on longevity biotech
Attività
-
A new paper in Nature Aging suggests age-related changed are nonlinear, and change is most rapid around ages 45 and 60. As someone rapidly…
A new paper in Nature Aging suggests age-related changed are nonlinear, and change is most rapid around ages 45 and 60. As someone rapidly…
Consigliato da Marco Dotto
-
I signed the new petition to create the National Institute for Longevity and Aging Research (NILAR) https://lnkd.in/gVFk-5-S I included the following…
I signed the new petition to create the National Institute for Longevity and Aging Research (NILAR) https://lnkd.in/gVFk-5-S I included the following…
Consigliato da Marco Dotto
-
Join us on August 21 for a seminar in our Longevity Biotech Group by Dr. Michael Levin: "Agential Interventions: From Diverse Intelligence to…
Join us on August 21 for a seminar in our Longevity Biotech Group by Dr. Michael Levin: "Agential Interventions: From Diverse Intelligence to…
Consigliato da Marco Dotto
Esperienza
Formazione
Esperienze di volontariato
-
Scientific committee member
Open BioMedical Initiative
- Presente 8 anni e 5 mesi
Scienza e tecnologia
The Open BioMedical Initiative (OBM Initiative) is a global non profit initiative focused to develop open source, 3D printable and low cost health and accessibility supports. It collaborate with the traditional Biomedical field thanks to its online community of volunteers and a delocalized and collaborative design of the devices. Born in Italy, it is connected with a growing number of international collaborators who join its mission.
The organization and the projects of the Open…The Open BioMedical Initiative (OBM Initiative) is a global non profit initiative focused to develop open source, 3D printable and low cost health and accessibility supports. It collaborate with the traditional Biomedical field thanks to its online community of volunteers and a delocalized and collaborative design of the devices. Born in Italy, it is connected with a growing number of international collaborators who join its mission.
The organization and the projects of the Open BioMedical Initiative are the result of the work of its members from all over the World, united by passion, competence and curiosity. Inside it counts engineers, biotechnologists, doctors, makers, legals, journalists and general supporters, aiming to spread technologies at the service of health accessible to all.
-
-
Mentor
Hacking Talents
- Presente 3 anni
Mentor at Hacking Talents, the inspirational platform for your talents, which delivers pro-bono mentorship to help anyone looking for a career change
-
Volunteer
Hacking Covid - 19
- Presente 4 anni
Salute
Hacking Covid-19 is a collaborative Network of Italian Innovators who create and actively support projects focused on the COVID-19 Emergency
Corsi
-
Accounting and financial tools
-
-
Applied genomics technologies
BENG 183
-
Biochemical Engineering
BENG 161B
-
Biochemical Techniques
BIBC 103
-
Biology of cancer
BIMM 134
-
Bioreactor Engineering
BENG 161A
-
Business law (distribution and licensing)
-
-
Business law and investor relations
-
-
Business planning
-
-
Business project management
MGT 172
-
Competitive analysis
-
-
Human resources (law, planning, costs)
-
-
Intellectual property
-
-
Organizational leadership
MGT 164
-
Pharmacology
BIMM 118
-
Positioning and marketing
-
-
Process mapping and operations
-
-
Project management
-
-
Recombinant DNA techniques
BIMM 101
-
Regulation of gene activity in eucaryotic cells
BIMM 112
-
Sales strategies
-
-
Self empowerment
-
Lingue
-
Italian
Conoscenza madrelingua o bilingue
-
English
Conoscenza professionale completa
Altre attività di Marco
-
Why would anyone leave a scientific career to go build ... mouse tech? 90.4% of drugs fail in humans. It costs $2.3B and takes 12 years to get a…
Why would anyone leave a scientific career to go build ... mouse tech? 90.4% of drugs fail in humans. It costs $2.3B and takes 12 years to get a…
Consigliato da Marco Dotto
-
I am happy to share with you all our latest paper in which we defined a Multi-Omics Signature for Esophageal Adenocarcinoma Prediction. It has been a…
I am happy to share with you all our latest paper in which we defined a Multi-Omics Signature for Esophageal Adenocarcinoma Prediction. It has been a…
Consigliato da Marco Dotto
-
Much of dementia—perhaps half—could be prevented or substantially delayed with attention to 14 modifiable risk factors The Lancet Commission 2024…
Much of dementia—perhaps half—could be prevented or substantially delayed with attention to 14 modifiable risk factors The Lancet Commission 2024…
Consigliato da Marco Dotto
-
BioAge is pleased to announce the initiation of the STRIDES Phase 2 clinical trial evaluating azelaprag, an oral exercise mimetic, for the treatment…
BioAge is pleased to announce the initiation of the STRIDES Phase 2 clinical trial evaluating azelaprag, an oral exercise mimetic, for the treatment…
Consigliato da Marco Dotto
-
A few months ago, the business angels of IAG, led by Champions Alessandro Lattuada and Marco Dotto, invested in Rubedo Life Sciences, a…
A few months ago, the business angels of IAG, led by Champions Alessandro Lattuada and Marco Dotto, invested in Rubedo Life Sciences, a…
Consigliato da Marco Dotto
-
Questa è la storia di due giovanissimi che visto un problema non si girano dall'altra parte ma cercano di risolverlo. Lei è Chiara Schettino, ha 23…
Questa è la storia di due giovanissimi che visto un problema non si girano dall'altra parte ma cercano di risolverlo. Lei è Chiara Schettino, ha 23…
Consigliato da Marco Dotto
-
We are thrilled to announce another milestone for our portfolio company, Ochre Bio. Ochre Bio has entered into a multi-year data license agreement…
We are thrilled to announce another milestone for our portfolio company, Ochre Bio. Ochre Bio has entered into a multi-year data license agreement…
Consigliato da Marco Dotto
-
A new drug keeps mice healthier for longer and increases lifespan by 20–25%! The researchers dubbed mice taking the IL-11 antibodies ‘supermodel…
A new drug keeps mice healthier for longer and increases lifespan by 20–25%! The researchers dubbed mice taking the IL-11 antibodies ‘supermodel…
Consigliato da Marco Dotto
-
Check out my Longevity Summit Dublin presentation on longevity biotech (LongBio), Healthspan Capital, and ImmuneAGE Bio. https://lnkd.in/eF3JeD-f
Check out my Longevity Summit Dublin presentation on longevity biotech (LongBio), Healthspan Capital, and ImmuneAGE Bio. https://lnkd.in/eF3JeD-f
Consigliato da Marco Dotto
-
Our IPO @ Nasdaq is scheduled for mid (or early) August... If you are interested in more details, please visit our SEC S1 filing via this link:…
Our IPO @ Nasdaq is scheduled for mid (or early) August... If you are interested in more details, please visit our SEC S1 filing via this link:…
Consigliato da Marco Dotto
-
We are out of stealth mode and raising our seed round now !
We are out of stealth mode and raising our seed round now !
Consigliato da Marco Dotto
-
IMHO, the most impactful way to use AI in biopharma is to discover drugs with massive blockbuster potential and massive indication expansion…
IMHO, the most impactful way to use AI in biopharma is to discover drugs with massive blockbuster potential and massive indication expansion…
Consigliato da Marco Dotto
Altri profili simili
Altre persone che si chiamano Marco Dotto in Italia
Su LinkedIn ci sono altre 21 persone che si chiamano Marco Dotto in Italia
Vedi altre persone che si chiamano Marco Dotto